Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pelareorep + pembrolizumab + irinotecan
- Development stage
- Unknown
- Lead developer
- Oncolytics Biotech
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This drug is a combination therapy consisting of pelareorep (an intravenous oncolytic reovirus, also known as REOLYSIN), pembrolizumab (a monoclonal antibody immune checkpoint inhibitor targeting PD-1, branded as Keytruda), and irinotecan (a topoisomerase I inhibitor chemotherapy, branded as Camptosar). Pelareorep induces a T cell-inflamed tumor microenvironment by infecting and lysing cancer cells and promoting antiviral and antitumor immune responses. Pembrolizumab blocks the interaction between PD-1 and its ligands, enhancing T-cell mediated antitumor immunity. Irinotecan inhibits topoisomerase I, preventing DNA replication and cell division in cancer cells. This combination has been investigated in phase 1b clinical trials for metastatic pancreatic adenocarcinoma patients who progressed after first-line treatment. It is designed to synergistically activate anti-tumor immunity and cytotoxic activity, and has demonstrated safety and early signals of efficacy in this population[1][2][4][5][6][7].
- Other names
- pelareorep + pembrolizumab + irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pelareorep + pembrolizumab + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pelareorep + pembrolizumab + irinotecan.